S49. Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A
نویسنده
چکیده
Background Human cancer cells may suppress the adaptive immune response by expressing PD-L1 and down-regulating T cell activity through PD-L1/PD-1 and PD-L1/B7.1 interactions. Disruption of PD-L1 signaling restores antitumor immunity, resulting in durable responses across multiple human tumor types. Here we describe the clinical activity and development of predictive biomarkers for MPDL3280A, a human monoclonal antibody with an engineered Fc-domain designed to optimize safety and efficacy, that targets PD-L1 and prevents binding to receptors PD-1 and B7.1.
منابع مشابه
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A Marcin Kowanetz, Christina Rabe, Yuanyuan Xiao, Qun J Wu, Hartmut Koeppen, Cecilia Leddy, Rajesh D Patel, John Powderly, Holbrook Kohrt, Scott Gettinger, Jean-Charles Soria, Roy S Herbst, Rupal Desai, Mitchell Denker, Jane Ruppel, Marigold Boe, Rin Nakamu...
متن کاملP13. Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)
Methods Immunologic pharmacodynamics effects were evaluated in tumors and bloods from patients treated with MPDL3280A. MPDL3280A was administered IV q3w in >300 pts with locally advanced or metastatic solid tumors. PD-L1 and CD8 were measured by IHC. PD-L1 expression was evaluated in tumor and intra-tumoral immune cells. CD8 was assessed in the tumor center, periphery and invasive margin. The e...
متن کاملIntratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1
PD-L1, PD-L2 and other immune-related molecules regulate Th1 and Th2 immune responses. Tumor-expressed PD-L1, when bound to PD-1 or B7.1 on activated T cells, can mediate cancer immune evasion. While inhibiting PD-L1 receptor binding represents an attractive strategy to restore tumor-specific T-cell immunity, other immune-related factors and cell types within the tumor microenvironment affect a...
متن کاملMyeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer
Treatment options for metastatic urothelial bladder cancer (UBC) are limited. Mutational complexity is known to be high in UBC and may correlate with increased immunogenicity. MPDL3280A, a human PD-L1 monoclonal antibody containing an engineered Fc-domain designed to promote a Th1-driven response, has demonstrated a RECIST response rate of 43% in diagnostically selected, pretreated patients wit...
متن کاملA humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
Antibodies targeting the PD-1/PD-L1 immune checkpoint lead to tumor regression and improved survival in several cancers. PD-L1 expression in tumors may be predictive of response to checkpoint blockade therapy. Because tissue samples might not always be available to guide therapy, we developed and evaluated a humanized antibody for non-invasive imaging of PD-L1 expression in tumors. Radiolabeled...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2 شماره
صفحات -
تاریخ انتشار 2014